Zepbound vs Mounjaro: Long-Term Durability of Response

Why Zepbound and Mounjaro Are Pharmacologically Identical

Both brand names contain the same active pharmaceutical ingredient at the same concentrations. Eli Lilly received two separate FDA approvals for tirzepatide: Mounjaro in May 2022 for type 2 diabetes, and Zepbound in November 2023 for chronic weight management in adults with a BMI of 30 or above, or BMI <30 with at least one weight-related comorbidity. [1][2]

Because they are the same molecule, every durability trial conducted on tirzepatide applies equally to both products. There is no separate long-term dataset for "Zepbound durability" versus "Mounjaro durability." Clinicians and patients comparing the two brands are, in practice, asking one question: how long does tirzepatide keep working, and what happens when you stop?

Same Molecule, Different Indications

The regulatory split was a commercial decision, not a pharmacological one. Mounjaro's label targets HbA1c reduction. Zepbound's label targets weight reduction. The dosing schedule, injection device, and dose escalation protocol are identical across both products. [1]

What "Dual Agonism" Means for Durability

Tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. GLP-1 receptor activation suppresses appetite and slows gastric emptying. GIP receptor activation may improve GLP-1 sensitivity and modulate adipose tissue directly. [3] The additive effect on energy intake is one reason tirzepatide's weight-loss magnitude exceeds that of GLP-1-only agents like semaglutide 2.4 mg (Wegovy) in head-to-head data, though no randomized head-to-head trial has been published as of early 2025.

SURMOUNT-1: The Foundational Durability Dataset

SURMOUNT-1 enrolled 2,539 adults without diabetes (BMI of 30 or above, or BMI of 27 with at least one comorbidity) and randomized them to tirzepatide 5 mg, 10 mg, or 15 mg, or placebo for 72 weeks. [4]

Weight Loss at 72 Weeks

At 72 weeks, mean weight loss was:

• 5 mg: 15.0% of body weight
• 10 mg: 19.5% of body weight
• 15 mg: 20.9% of body weight
• Placebo: 3.1% of body weight

All three active doses showed P<0.001 versus placebo. At 15 mg, 89.5% of participants achieved at least 5% weight loss, 56.7% achieved at least 20% weight loss, and 36.2% achieved at least 25% weight loss. [4] These figures matter for durability because the depth of initial response predicts how much buffer a patient has before regain becomes clinically significant.

Tolerability Over Time

Gastrointestinal adverse events (nausea, diarrhea, vomiting) were most frequent during the dose-escalation phase and decreased substantially after reaching the maintenance dose. By week 20 to 24, nausea rates in the 15 mg group had fallen to levels only modestly above placebo. [4] Tolerability stabilization is relevant to durability: most discontinuations happen in the first 20 weeks, so participants who reach maintenance dose generally stay on therapy.

SURMOUNT-4: What Happens When You Stop

SURMOUNT-4 is the key trial for understanding what "durability of response" actually means when a patient stops tirzepatide. [5]

Trial Design

SURMOUNT-4 enrolled participants who had already completed 36 weeks of open-label tirzepatide and achieved at least 10% weight loss. They were then randomized to continue tirzepatide or switch to placebo for an additional 52 weeks.

The Regain Data

Participants who continued tirzepatide lost an additional 5.5% of body weight over the 52-week extension. Those switched to placebo regained approximately 14% of their starting body weight within 52 weeks. By the end of the observation period, the difference in total weight loss between the continuation and withdrawal groups was 21.8 percentage points. [5]

This finding carries a direct clinical message: tirzepatide's durability is contingent on continued use. The drug suppresses the physiological drivers of weight regain (elevated ghrelin, reduced leptin sensitivity, increased appetite) only while it remains active in the body. Stopping the medication allows those signals to re-emerge.

Implications for Brand Switching

A patient switching from Mounjaro to Zepbound, or from Zepbound to Mounjaro, does not stop tirzepatide. They continue the same molecule at the same dose. SURMOUNT-4's regain data therefore does not apply to brand switches, only to actual discontinuation.

SURPASS-2: Durability in Type 2 Diabetes

SURPASS-2 compared tirzepatide (5, 10, and 15 mg) against semaglutide 1 mg (Ozempic) in 1,879 adults with type 2 diabetes over 40 weeks. [6]

HbA1c Outcomes

Mean HbA1c reductions at 40 weeks:

• Tirzepatide 5 mg: 2.09%
• Tirzepatide 10 mg: 2.37%
• Tirzepatide 15 mg: 2.46%
• Semaglutide 1 mg: 1.86%

All tirzepatide doses outperformed semaglutide 1 mg (P<0.001 for each comparison). [6] At 15 mg, 92% of participants reached HbA1c below 7.0%, and 47% reached HbA1c below 5.7% (normal range).

Weight Loss in People with Diabetes

Even in the SURPASS-2 population (which includes the metabolic resistance associated with type 2 diabetes), weight loss with tirzepatide 15 mg reached 12.4 kg at 40 weeks versus 6.2 kg for semaglutide 1 mg. [6] This weight benefit compounds glycemic durability: lower body weight reduces insulin resistance, which in turn makes the drug's HbA1c benefit more sustainable.

Durability Beyond 40 Weeks

The SURPASS-PLUS and open-label extension data suggest that both HbA1c and body weight reductions are maintained through 104 weeks in people with type 2 diabetes who remain on tirzepatide, though dropout-related bias in open-label extensions warrants caution when interpreting those figures. [7]

SURMOUNT-3: High-Intensity Lifestyle Run-In Data

SURMOUNT-3 added a 12-week intensive lifestyle intervention run-in before randomization. Participants who achieved at least 5% weight loss during the run-in were then randomized to tirzepatide 10 mg or 15 mg versus placebo. [8]

At 72 weeks from randomization (84 weeks total), the tirzepatide groups maintained an additional 18.4% mean weight reduction from the post-run-in body weight. This suggests that tirzepatide's durability is additive to, not a substitute for, lifestyle change. Patients who enter pharmacotherapy with established behavioral habits appear to sustain responses better.

Real-World Durability: What Claims Data Show

Trial populations are not always representative of clinical practice. Early real-world pharmacy claims analyses show that tirzepatide persistence at 12 months is approximately 45 to 55%, compared to roughly 35 to 40% for semaglutide 2.4 mg (Wegovy) in the same databases. [9]

The higher persistence with tirzepatide may reflect its greater weight-loss magnitude (patients who see more change tend to stay on therapy) or its dosing flexibility (the 2.5 mg starting dose allows slower escalation for tolerability-sensitive patients).

Insurance Coverage and Real-World Continuity

One factor that disrupts real-world durability more than pharmacology is insurance coverage loss. Mounjaro is covered by many commercial plans for diabetes. Zepbound has Medicare Part D coverage for obesity as of January 2025. Gaps in coverage force dose reductions or discontinuation, which the SURMOUNT-4 data show directly translate to weight regain. Continuous coverage is as important to durability as the drug's mechanism.

The HealthRX Durability Decision Framework

Clinicians on the HealthRX medical team use the following decision logic when a patient asks whether to stay on Mounjaro or switch to Zepbound:

1. Primary indication: If the patient has type 2 diabetes, Mounjaro is the on-label choice and typically has stronger insurance support. If the patient's primary goal is weight management without diabetes, Zepbound is on-label and avoids off-label prescribing concerns.
2. Current dose: Because doses are identical between brands, no pharmacological adjustment is needed. A patient on Mounjaro 10 mg moves to Zepbound 10 mg with the same injection schedule.
3. Coverage continuity: Switching brands solely for cost savings can backfire if prior authorization for the new brand is delayed. A 4-to-8-week coverage gap is enough to produce meaningful weight regain per SURMOUNT-4 data.
4. Response trajectory: Patients who have not reached at least 5% weight loss after 16 weeks at a tolerated maintenance dose should discuss dose escalation rather than brand switching, because the molecule is the same regardless of label.

Comparing Durability Across GLP-1 and Dual-Agonist Agents

Tirzepatide is not the only option in the weight-management space. Comparing durability across agents helps contextualize the SURMOUNT data.

Semaglutide 2.4 mg (Wegovy): STEP-1

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo. [10] After treatment withdrawal in the STEP-1 extension, participants regained approximately two-thirds of their lost weight within 1 year. The SURMOUNT-4 regain pattern (approximately 14 percentage points regained in 52 weeks after stopping) is quantitatively similar, suggesting that weight regain after stopping is a class effect rather than a tirzepatide-specific vulnerability.

Liraglutide 3 mg (Saxenda): SCALE Obesity

SCALE Obesity (N=3,731) showed 8.4% mean weight loss at 56 weeks with liraglutide 3 mg. [11] Durability was lower than semaglutide or tirzepatide, and regain after stopping was rapid. Liraglutide is now rarely the first-choice agent where tirzepatide or semaglutide 2.4 mg are available and covered.

Practical Takeaway on Class Comparisons

Tirzepatide 15 mg produces the deepest mean weight loss of any currently approved pharmacotherapy. Depth of initial response translates to a larger buffer before regain becomes symptomatic or clinically significant, which is one reason clinicians often describe tirzepatide as having "more durable" results. The mechanism is quantitative (more weight lost means more weight available to regain before baseline) rather than a unique sustained biological effect.

Dose Escalation and Its Role in Long-Term Response

The starting dose of 2.5 mg weekly is sub-therapeutic for weight loss. Dose escalation every 4 weeks to a target of 10 mg or 15 mg is expected protocol. [1] Patients who plateau at lower doses (5 mg or 7.5 mg) because of tolerability constraints will see less weight loss and may incorrectly attribute the plateau to the drug "wearing off."

Differentiating True Loss of Response from Plateau

True loss of response to tirzepatide at a stable maintenance dose is uncommon in trial data. The SURMOUNT-1 weight-loss curves plateau around week 36 to 48 and then remain stable through week 72 without meaningful upward drift. [4] A patient who sees weight creep after several months of stability is more likely experiencing:

• Dietary or behavioral drift
• A medication adherence issue (missed injections)
• A new metabolic stressor (thyroid dysfunction, new medications that cause weight gain)

These factors should be assessed before attributing the change to pharmacological tolerance.

Injection Site Rotation and Absorption

Tirzepatide is injected subcutaneously into the abdomen, thigh, or upper arm. Rotating injection sites reduces local lipohypertrophy, which can slow absorption and reduce effective drug levels without changing the dose on the prescription label. Patients who inject consistently into the same site may experience unexplained response blunting correctable by simple rotation.

Switching from Zepbound to Mounjaro (or Vice Versa): Clinical Protocol

The most common reason for switching is insurance. A patient whose plan covers Mounjaro but not Zepbound (or the reverse) faces a forced brand change that should not require any clinical adjustment.

Step-by-Step Switching Protocol

1. Confirm the current dose (e.g., tirzepatide 7.5 mg weekly).
2. Write or update the prescription to the new brand at the identical dose and frequency.
3. Instruct the patient to use the first pen of the new brand on the same day of the week they would have used the prior brand. No loading dose. No overlap.
4. Monitor for any unusual tolerability changes. These would be unexpected, since the molecule is identical, but could reflect minor formulation excipient differences or patient anxiety driving symptom reporting.
5. Verify insurance approval for the new brand before the patient's current supply runs out. A lapse of more than 2 to 3 weeks should prompt proactive re-initiation planning.

What the Prescriber Letter Should Say

The American Association of Clinical Endocrinology (AACE) guidance on GLP-1 and dual agonist therapy does not treat brand switching within the same molecule as a clinical event requiring re-titration. [12] Prescribers should document the brand change in the chart, note the clinical rationale (insurance or formulary), and confirm the dose equivalence explicitly to the dispensing pharmacy to avoid errors.

Frequently Asked Questions